1. Home
  2. EARN vs TNXP Comparison

EARN vs TNXP Comparison

Compare EARN & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • TNXP
  • Stock Information
  • Founded
  • EARN 2012
  • TNXP 2007
  • Country
  • EARN United States
  • TNXP United States
  • Employees
  • EARN N/A
  • TNXP N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • TNXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • EARN Real Estate
  • TNXP Health Care
  • Exchange
  • EARN Nasdaq
  • TNXP Nasdaq
  • Market Cap
  • EARN 189.7M
  • TNXP 173.9M
  • IPO Year
  • EARN 2013
  • TNXP N/A
  • Fundamental
  • Price
  • EARN $5.24
  • TNXP $19.85
  • Analyst Decision
  • EARN Buy
  • TNXP Buy
  • Analyst Count
  • EARN 2
  • TNXP 1
  • Target Price
  • EARN $5.88
  • TNXP $70.00
  • AVG Volume (30 Days)
  • EARN 356.9K
  • TNXP 952.7K
  • Earning Date
  • EARN 11-11-2025
  • TNXP 11-11-2025
  • Dividend Yield
  • EARN 18.32%
  • TNXP N/A
  • EPS Growth
  • EARN N/A
  • TNXP N/A
  • EPS
  • EARN N/A
  • TNXP N/A
  • Revenue
  • EARN $35,893,000.00
  • TNXP $9,831,000.00
  • Revenue This Year
  • EARN N/A
  • TNXP $14.79
  • Revenue Next Year
  • EARN $15.96
  • TNXP $933.49
  • P/E Ratio
  • EARN N/A
  • TNXP N/A
  • Revenue Growth
  • EARN 43.30
  • TNXP N/A
  • 52 Week Low
  • EARN $4.33
  • TNXP $6.76
  • 52 Week High
  • EARN $7.11
  • TNXP $130.00
  • Technical
  • Relative Strength Index (RSI)
  • EARN 43.09
  • TNXP 30.90
  • Support Level
  • EARN $5.10
  • TNXP $18.17
  • Resistance Level
  • EARN $5.20
  • TNXP $20.69
  • Average True Range (ATR)
  • EARN 0.10
  • TNXP 1.27
  • MACD
  • EARN 0.01
  • TNXP 0.25
  • Stochastic Oscillator
  • EARN 49.60
  • TNXP 24.78

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: